Sandusky, Ohio-based PAO Group launched its first CBD nutraceutical product, a sleep aid called RelaxRX CBD. According to market analyst Facts & Factors, the sleep aid market was projected at $64.29 billion in 2019 and is forecast to hit $101.7 billion in 2026.
RelaxRX is available in 30 milligram softgels and in an 1,800 milligram tincture. The CBD oil is 100% derived from full spectrum whole plant hemp oil and contains no added chemicals.
PAOG has confirmed shipping its first CBD nutraceutical product to its distribution partner, North American Cannabis Holdings Inc. The product will soon be for sale online at www.USMJ.com.
PAOG expects revenue to grow rapidly following the RelaxRX product launch as the company has products lined up to follow RelaxRX, adding to the overall sales potential. PAOG plans to announce its next CBD nutraceutical later this month.
Last year, PAOG acquired intellectual property derived through research into CBD extracted in association with a patented extraction method. PAOG is developing both pharmaceutical and nutraceutical treatments based on that research.
